Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise
Sanofi’s new trispecific technology could provide a growth platform for the pharma’s cancer franchise
Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron.
Sanofi (Euronext:SAN; NYSE:SNY) has been striving to expand its cancer franchise as its relationship with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) winds down.
Last year, Sanofi hired John Reed as EVP and global head of R&D, pulling him from Roche (SIX:ROG; OTCQB:RHHBY), which has led pharmas in cancer sales for years, where he was global head of the Pharma Research and Early Development unit.
Much of Sanofi’s oncology pipeline stems from a 2007 discovery collaboration and a 2015 immuno-oncology deal with Regeneron.
Both deals have been productive. Cancer programs now account for the largest part of Sanofi’s pipeline, making up about one third of its clinical candidates. The first deal ended in